Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cartesian Therapeutics, Inc. - Common Stock (NQ:RNAC)

13.33 -0.13 (-0.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,764
Open 13.46
Bid (Size) 11.50 (1)
Ask (Size) 14.54 (3)
Prev. Close 13.46
Today's Range 12.56 - 13.54
52wk Range 8.460 - 26.50
Shares Outstanding 115,079,292
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG. 
Via Benzinga
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027. 
Via Benzinga

Performance

YTD
-21.3%
-21.3%
1 Month
+16.3%
+16.3%
3 Month
+9.2%
+9.2%
6 Month
-31.4%
-31.4%
1 Year
-23.8%
-23.8%

More News

Read More
US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert
Via Benzinga
Topics Government World Trade
Why Venus Concept Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients
Via Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Via Investor's Business Daily
RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs
Via Investor's Business Daily
Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M
Via Benzinga
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Cartesian Therapeutics Announces New Employment Inducement Grants
From Cartesian Therapeutics, Inc.
Via Business Wire
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
From Cartesian Therapeutics, Inc.
Via Business Wire
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Via Benzinga
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Cartesian Therapeutics, Inc.
Via Business Wire
Cartesian Therapeutics Announces New Employment Inducement Grants
From Cartesian Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
LivePerson And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
SolarEdge Layoffs 2024: What to Know About the Latest SEDG Job Cuts
Via InvestorPlace
Topics Workforce

Frequently Asked Questions

Is Cartesian Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cartesian Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cartesian Therapeutics, Inc. - Common Stock trade on?
Cartesian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cartesian Therapeutics, Inc. - Common Stock?
The ticker symbol for Cartesian Therapeutics, Inc. - Common Stock is RNAC on the Nasdaq Stock Market
What is the current price of Cartesian Therapeutics, Inc. - Common Stock?
The current price of Cartesian Therapeutics, Inc. - Common Stock is 13.33
When was Cartesian Therapeutics, Inc. - Common Stock last traded?
The last trade of Cartesian Therapeutics, Inc. - Common Stock was at 07/25/25 04:00 PM ET
What is the market capitalization of Cartesian Therapeutics, Inc. - Common Stock?
The market capitalization of Cartesian Therapeutics, Inc. - Common Stock is 1.53B
How many shares of Cartesian Therapeutics, Inc. - Common Stock are outstanding?
Cartesian Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.